Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT Trials: clinical findings of a rare disease
Standard
Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT Trials: clinical findings of a rare disease. / Friedrich, Carsten; Warmuth-Metz, Monika; von Bueren, André O; Nowak, Johannes; Bison, Brigitte; von Hoff, Katja; Pietsch, Torsten; Kortmann, Rolf D; Rutkowski, Stefan.
In: J NEUROSURG-PEDIATR, Vol. 15, No. 3, 03.2015, p. 227-35.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT Trials: clinical findings of a rare disease
AU - Friedrich, Carsten
AU - Warmuth-Metz, Monika
AU - von Bueren, André O
AU - Nowak, Johannes
AU - Bison, Brigitte
AU - von Hoff, Katja
AU - Pietsch, Torsten
AU - Kortmann, Rolf D
AU - Rutkowski, Stefan
PY - 2015/3
Y1 - 2015/3
N2 - OBJECT: Primitive neuroectodermal tumors of the central nervous system (CNS-PNET) arising in the brainstem are extremely rare, and knowledge about them is limited. The few existing case series report fatal outcomes. The purpose of this study was to analyze clinical characteristics of and outcome for brainstem CNS-PNET patients treated according to the consecutive, population-based HIT studies covering a 19-year time period.METHODS: Between September 1992 and November 2011, 6 eligible children with histologically proven brainstem CNS-PNET not otherwise specified and 2 children with brainstem ependymoblastomas (3, partial resection; 3, subtotal resection; 2, biopsy), median age 3.3 years (range 1.2-10.6 years), were treated according to consecutive multimodal HIT protocols for CNS-PNET/medulloblastoma. Postoperative treatment was according to maintenance chemotherapy protocols (3, craniospinal irradiation [CSI] followed by maintenance chemotherapy), sandwich chemotherapy protocols (2, neoadjuvant chemotherapy, CSI, maintenance chemotherapy), or a therapy protocol for children younger than 4 years (3, postoperative chemotherapy followed by CSI).RESULTS: The median duration of prediagnostic symptoms, predominantly cranial nerve deficits (n = 7), pyramidal tract signs (n = 5), or ataxia (n = 5), was 5 weeks (range 1-13 weeks). The tumors were all located in the pons. Most involved more than half of the pontine axial diameter and were sharply marginated. All patients had postoperative residual disease, including metastasis in 1 case. With 1 exception all tumors progressed early during treatment within 3.9 months (range 2.5-10.4 months), leading to a 1-year event-free survival rate (± standard error) of 13% ± 12%. After progression, patients succumbed early to their disease resulting in a 1-year overall survival rate of 25% ± 15%. The only surviving patient had a partially resected CNS-PNET, received a sandwich chemotherapy protocol, and is without disease progression 14 months after diagnosis.CONCLUSIONS: CNS-PNET is a rare but important differential diagnosis in childhood brainstem tumors. So far, efficient therapies are lacking. The sampling of tumor material for improved biological understanding and identification of new therapeutic targets is important.
AB - OBJECT: Primitive neuroectodermal tumors of the central nervous system (CNS-PNET) arising in the brainstem are extremely rare, and knowledge about them is limited. The few existing case series report fatal outcomes. The purpose of this study was to analyze clinical characteristics of and outcome for brainstem CNS-PNET patients treated according to the consecutive, population-based HIT studies covering a 19-year time period.METHODS: Between September 1992 and November 2011, 6 eligible children with histologically proven brainstem CNS-PNET not otherwise specified and 2 children with brainstem ependymoblastomas (3, partial resection; 3, subtotal resection; 2, biopsy), median age 3.3 years (range 1.2-10.6 years), were treated according to consecutive multimodal HIT protocols for CNS-PNET/medulloblastoma. Postoperative treatment was according to maintenance chemotherapy protocols (3, craniospinal irradiation [CSI] followed by maintenance chemotherapy), sandwich chemotherapy protocols (2, neoadjuvant chemotherapy, CSI, maintenance chemotherapy), or a therapy protocol for children younger than 4 years (3, postoperative chemotherapy followed by CSI).RESULTS: The median duration of prediagnostic symptoms, predominantly cranial nerve deficits (n = 7), pyramidal tract signs (n = 5), or ataxia (n = 5), was 5 weeks (range 1-13 weeks). The tumors were all located in the pons. Most involved more than half of the pontine axial diameter and were sharply marginated. All patients had postoperative residual disease, including metastasis in 1 case. With 1 exception all tumors progressed early during treatment within 3.9 months (range 2.5-10.4 months), leading to a 1-year event-free survival rate (± standard error) of 13% ± 12%. After progression, patients succumbed early to their disease resulting in a 1-year overall survival rate of 25% ± 15%. The only surviving patient had a partially resected CNS-PNET, received a sandwich chemotherapy protocol, and is without disease progression 14 months after diagnosis.CONCLUSIONS: CNS-PNET is a rare but important differential diagnosis in childhood brainstem tumors. So far, efficient therapies are lacking. The sampling of tumor material for improved biological understanding and identification of new therapeutic targets is important.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Brain Stem Neoplasms
KW - Chemotherapy, Adjuvant
KW - Child
KW - Child, Preschool
KW - Disease Progression
KW - Disease-Free Survival
KW - Drug Administration Schedule
KW - Female
KW - Humans
KW - Infant
KW - Maintenance Chemotherapy
KW - Male
KW - Neoadjuvant Therapy
KW - Neoplasm, Residual
KW - Neuroectodermal Tumors, Primitive
KW - Pons
KW - Rare Diseases
U2 - 10.3171/2014.9.PEDS14213
DO - 10.3171/2014.9.PEDS14213
M3 - SCORING: Journal article
C2 - 25555122
VL - 15
SP - 227
EP - 235
JO - J NEUROSURG-PEDIATR
JF - J NEUROSURG-PEDIATR
SN - 1933-0707
IS - 3
ER -